These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29227571)

  • 1. Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial.
    Ji L; Liu J; Yang J; Li Y; Liang L; Zhu D; Li Q; Ma T; Xu H; Yang Y; Zeng J; Feng B; Qu S; Li Y; Ma L; Lin S; Wang J; Li W; Song W; Li X; Luo Y; Xi S; Lin M; Liu Y; Liang Z
    Diabetes Obes Metab; 2018 Apr; 20(4):1006-1013. PubMed ID: 29227571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes.
    Aggarwal N; Singla A; Mathieu C; Montanya E; Pfeiffer AFH; Johnsson E; Zhao J; Iqbal N; Bailey C
    Diabetes Obes Metab; 2018 Feb; 20(2):463-467. PubMed ID: 28857388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
    Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
    Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
    Fonseca V; Zhu T; Karyekar C; Hirshberg B
    Diabetes Obes Metab; 2012 Apr; 14(4):365-71. PubMed ID: 22192246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
    Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ
    Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
    Derosa G; D'Angelo A; Romano D; Maffioli P
    Drug Des Devel Ther; 2017; 11():1481-1488. PubMed ID: 28553078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
    Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
    Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study).
    Du J; Liang L; Fang H; Xu F; Li W; Shen L; Wang X; Xu C; Bian F; Mu Y
    Diabetes Obes Metab; 2017 Nov; 19(11):1513-1520. PubMed ID: 28296055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose Comparison And Side Effect Profile Of Metformin Extended Release Versus Metformin Immediate Release.
    Hameed M; Khan K; Salman S; Mehmood N
    J Ayub Med Coll Abbottabad; 2017; 29(2):225-229. PubMed ID: 28718236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of body mass index or dosage on gastrointestinal disorders associated with extended-release metformin in type 2 diabetes: Sub-analysis of a Phase IV open-label trial in Chinese patients.
    Guo L; Guo X; Li Y; Hong X; Jiang X; Su Q; Zhao D; Wu X; Ji L
    Diabetes Metab Syndr; 2016; 10(3):137-42. PubMed ID: 26948203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study.
    Ji L; Li L; Ma J; Li X; Li D; Meng B; Lu W; Sun J; Liu Y; Takayanagi G; Wang Y
    Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00222. PubMed ID: 33855222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
    Aschner P; Katzeff HL; Guo H; Sunga S; Williams-Herman D; Kaufman KD; Goldstein BJ;
    Diabetes Obes Metab; 2010 Mar; 12(3):252-61. PubMed ID: 20070351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC).
    Gao B; Gao W; Wan H; Xu F; Zhou R; Zhang X; Ji Q
    Diabetes Obes Metab; 2022 Jun; 24(6):991-999. PubMed ID: 35112779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.
    Yang W; Liu J; Shan Z; Tian H; Zhou Z; Ji Q; Weng J; Jia W; Lu J; Liu J; Xu Y; Yang Z; Chen W
    Lancet Diabetes Endocrinol; 2014 Jan; 2(1):46-55. PubMed ID: 24622668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Schweizer A; Dejager S; Bosi E
    Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E; Dotta F; Jia Y; Goodman M
    Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.
    Guo L; Chen L; Chang B; Yang L; Liu Y; Feng B
    Diabetes Obes Metab; 2018 Dec; 20(12):2740-2747. PubMed ID: 29961975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.